COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ, Simona SLEZÁKOVÁ, Radim LÍČENÍK, Abul Kalam NAJMI and Miloslav KLUGAR. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Environmental Research and Public Health. Basel: MDPI, 2021, vol. 18, No 19, p. 1-18. ISSN 1660-4601. Available from: https://dx.doi.org/10.3390/ijerph181910340.

Basic information

• Original name: COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
• Authors: HUSSAIN, Mohammad Salman (356 India, belonging to the institution), Harveen BAXI, Abanoub RIAD (818 Egypt, belonging to the institution), Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Simona SLEZÁKOVÁ (203 Czech Republic, belonging to the institution), Radim LÍČENÍK (203 Czech Republic, belonging to the institution), Abul Kalam NAJMI and Miloslav KLUGAR (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Environmental Research and Public Health, Basel, MDPI, 2021, 1660-4601.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30304 Public and environmental health
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 4.614
• RIV identification code: RIV/00216224:14110/21:00122477
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3390/ijerph181910340
• UT WoS: 000707124900001
• Keywords in English: COVID-19; diabetes; epidemiology; evidence; mortality; mucormycosis; mycoses; public health
• Tags: 14110525, 14110611, 14119612, 14119613, rivok
• Tags: International impact, Reviewed

Abstract

Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.

Links

• EF18_053/0016952, research and development project: Name: Postdoc2MUNI
• LTC20031, research and development project: Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST

• MUNI/A/1608/2020, interní kód MU: Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

Investor: Masaryk University

• MUNI/IGA/1543/2020, interní kód MU: Name: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Acronym: Evidence-Based Practice in Czechia)

Investor: Masaryk University